Myostatin Inhibitors Australia: What Does the Research Actually Show?
Myostatin inhibitors are being studied for their ability to preserve and increase muscle mass. Animal studies have produced remarkable results, while newer human trials are beginning to show where this research could realistically lead.
Last updated: August 2026Myostatin inhibitors have attracted growing interest because they target one of the body’s natural mechanisms for limiting muscle growth.
In animal experiments, blocking myostatin has caused substantial increases in skeletal muscle mass, including in adult animals that were not placed through a resistance training program.
More recently, researchers have investigated whether myostatin inhibition could help people retain more muscle while losing weight with medicines such as semaglutide.
The results are exciting, but there is an important difference between what has been achieved in animals and what has so far been demonstrated in humans.
Myostatin acts like one of the body’s natural brakes on muscle growth. Myostatin inhibitors attempt to reduce that braking signal.
What is myostatin?
Myostatin is a naturally occurring protein produced mainly in skeletal muscle.
Its scientific name is growth differentiation factor 8, commonly shortened to GDF-8.
Myostatin helps regulate how much skeletal muscle the body develops.
One of the easiest ways to understand myostatin is to think of it as a biological brake on muscle growth.
When myostatin sends its signal, it helps place a limit on how large muscles become.
When that signal is reduced, some of the normal restriction on muscle growth is removed.
GDF-8
signalling
is restricted
inhibitor
is reduced
on muscle growth
Scientists became particularly interested in this pathway after studying animals with naturally occurring or experimentally created myostatin deficiencies.
Animals with very low levels of functioning myostatin can develop unusually large muscles.
This effect has been observed in mice, cattle, dogs and other species.
Rare mutations affecting myostatin signalling have also been documented in humans with unusually high muscle mass.
What is a myostatin inhibitor?
A myostatin inhibitor is a drug or experimental therapy designed to reduce the activity of myostatin or interfere with the pathway through which myostatin limits muscle growth.
There is no single type of myostatin inhibitor.
Different myostatin inhibitors can affect different parts of the pathway. A drug that selectively blocks myostatin is not necessarily equivalent to a drug that also blocks activin or other related proteins.
Can myostatin inhibitors build muscle without exercise?
Animal research shows that meaningful muscle growth can occur after myostatin inhibition without a resistance training program.
This is one of the findings that made the pathway so interesting.
Normally, resistance training provides a physical stimulus that causes skeletal muscle to adapt and grow.
Myostatin inhibition works through a different mechanism.
Instead of providing a stronger growth stimulus, researchers reduce one of the biological signals that normally limits growth.
Approximate increase across individual skeletal muscles in an early adult mouse antibody study.
The early mouse study recorded significant changes over a relatively short treatment period.
Newer animal research explored preserving or increasing muscle during substantial weight loss.
This does not mean exercise becomes unnecessary. Training also develops strength, coordination, tendons, connective tissue, cardiovascular fitness and movement specific adaptations.
The early JA16 myostatin inhibitor study
JA16 anti-myostatin antibody
One of the most important early experiments was published in 2003 by Whittemore and colleagues.
Researchers developed an anti-myostatin monoclonal antibody known as JA16.
Importantly, the researchers treated adult mice rather than animals that had been genetically modified from birth.
After approximately two to four weeks of treatment, individual skeletal muscles increased by around 13% to 30%, depending on the muscle examined.
Grip strength also increased.
This provided an important proof of concept.
It showed that researchers did not need to remove myostatin genetically from birth to affect adult muscle mass.
Temporarily interfering with the pathway in an already developed animal could still produce substantial changes.
The recent myostatin and GLP-1 animal research
One of the most interesting developments in the field was published in Nature Communications in 2025.
Researchers wanted to know whether muscle preserving drugs could improve the type of weight lost during treatment with semaglutide.
Semaglutide can cause substantial weight loss, but some of that weight can come from lean tissue as well as body fat.
Researchers therefore investigated two antibodies:
A monoclonal antibody designed to bind and inhibit myostatin, also known as GDF-8.
A monoclonal antibody targeting activin A, another protein involved in overlapping muscle regulation pathways.
What happened in mice?
Obese male mice were treated with semaglutide alone or combinations involving myostatin and activin A blockade.
Blocking these muscle regulating signals altered the type of weight the animals lost.
The researchers reported greater fat loss while protecting lean mass.
Under some experimental conditions, lean mass actually increased despite the animals losing total body weight.
What happened in monkeys?
Researchers then tested the approach in obese male cynomolgus monkeys over a 20 week period.
The results followed a similar pattern.
Myostatin and activin A blockade improved lean mass preservation while allowing substantial fat loss.
Many dramatic findings in mice fail to translate into larger mammals. Seeing a similar body composition effect in non-human primates made the findings considerably more interesting.
What happened when myostatin inhibition was tested in humans?
Human evidence is now becoming more interesting, but it is important not to exaggerate what has been demonstrated.
One of the most relevant studies is Regeneron’s Phase 2 COURAGE trial.
The study investigated semaglutide alone and semaglutide combined with trevogrumab.
Another treatment group also received garetosmab.
26 week results
In the completed 26 week results reported in 2025, approximately 33% of the total weight lost with semaglutide alone came from lean mass.
Adding trevogrumab prevented approximately half of that lean mass loss.
Fat loss also increased.
The dramatic muscle growth commonly discussed online comes mainly from animal studies and rare genetic cases. Recent human research is showing meaningful lean mass preservation rather than extreme effortless muscle growth.
What happened when activin A was also blocked?
Adding garetosmab appeared capable of preserving even more lean tissue.
However, the three drug combination was also associated with more treatment discontinuations due to tolerability and adverse effects.
This highlights an important challenge.
Blocking more of the muscle restriction pathway may produce stronger body composition effects, but stronger effects do not automatically mean a safer or better treatment.
Which myostatin inhibitors are being researched?
Several pharmaceutical compounds are targeting myostatin or related muscle regulation pathways.
| Compound | Target | Type | Research interest |
|---|---|---|---|
| Trevogrumab | Myostatin / GDF-8 | Monoclonal antibody | Studied alongside semaglutide for muscle preservation during weight loss |
| Apitegromab | Pro and latent myostatin | Monoclonal antibody | Selective myostatin inhibition and advanced neuromuscular research |
| SRK-439 | Pro and latent myostatin | Investigational antibody | Being investigated for muscle preservation and obesity related applications |
| Garetosmab | Activin A | Monoclonal antibody | Studied alongside myostatin inhibition |
| Bimagrumab | Activin type II receptors | Monoclonal antibody | Broader pathway approach affecting muscle and body composition |
Compounds such as garetosmab and bimagrumab target related parts of the same broader muscle signalling system. They are often discussed alongside myostatin inhibitors because the pathways overlap.
What is trevogrumab?
Trevogrumab, previously known as REGN1033, is an experimental monoclonal antibody developed by Regeneron.
It is designed to bind to myostatin and reduce its activity.
Trevogrumab is currently one of the most interesting compounds in the field because it has been studied across several levels of research.
- Mouse studies
- Non-human primate studies
- Human clinical trials
- Combination research with semaglutide
Its current obesity research is primarily focused on improving the quality of weight loss.
In other words, the aim is for more weight to come from body fat while preserving a greater amount of muscle.
Trevogrumab provides some of the clearest current human evidence that directly inhibiting myostatin can meaningfully change body composition.
What is apitegromab?
Apitegromab is a selective monoclonal antibody developed by Scholar Rock.
It works differently from an antibody that simply binds circulating active myostatin.
Apitegromab binds to pro-myostatin and latent myostatin.
These are inactive precursor forms of the protein.
By targeting the protein before activation, the goal is to selectively reduce myostatin signalling without unnecessarily interfering with closely related signalling molecules.
Apitegromab has reached advanced clinical development for spinal muscular atrophy.
This is a medical application involving neuromuscular disease and should not be confused with approval for bodybuilding or general muscle enhancement.
One of the major goals of newer myostatin research is to affect skeletal muscle while disturbing as few other biological pathways as possible.
Are myostatin inhibitors peptides?
Not necessarily.
The term myostatin inhibitor describes what a compound does rather than the type of molecule it is.
Several of the most advanced compounds in this field are monoclonal antibodies.
Trevogrumab and apitegromab are examples.
Monoclonal antibodies are large biological medicines and are very different from the smaller research peptides commonly sold through peptide suppliers.
A supplement or research product advertised as a “myostatin blocker” should not automatically be assumed to reproduce the effects of pharmaceutical antibodies used in published research.
Does more muscle mean more strength?
Not necessarily.
This has been one of the major lessons from earlier myostatin research.
Some experimental therapies have increased lean mass or muscle volume without producing an equally large improvement in physical function.
Resistance training changes much more than the size of a muscle.
This is why current researchers increasingly look at strength and physical function rather than only measuring lean mass on scans.
Why have previous myostatin drugs struggled?
Myostatin inhibition has been researched for more than two decades.
If the pathway is capable of producing such dramatic changes in animals, it is reasonable to ask why these medicines are not already widely used.
Human biology is different
Mice can show much larger responses to experimental muscle therapies than humans.
A result in a mouse cannot automatically be expected to occur at the same scale in a person.
Genetic deficiency is different from temporary treatment
An animal that develops throughout life with little functioning myostatin is biologically different from an adult receiving an antibody for several months.
More muscle does not guarantee better function
A drug can increase measured lean mass but still fail to produce a meaningful improvement in mobility or strength.
The pathway affects more than one protein
Myostatin belongs to the broader TGF beta family of proteins.
Some earlier approaches affected several related signals rather than only myostatin.
This can create biological effects outside skeletal muscle.
Safety requirements are high
The acceptable risk of a medicine for someone with a severe muscle wasting disease is different from the acceptable risk for a healthy person simply wanting more muscle.
Could myostatin inhibitors replace anabolic steroids?
Current evidence does not support treating myostatin inhibitors as a direct replacement for anabolic steroids.
The two approaches work through different biological systems.
Anabolic androgenic steroids act primarily through androgen receptors.
Myostatin inhibitors attempt to reduce a signal that normally restricts muscle growth.
If highly effective myostatin inhibitors eventually become available, there would clearly be potential interest from bodybuilding and athletic communities.
Current pharmaceutical research, however, is primarily focused on medical conditions and muscle preservation rather than performance enhancement.
What could myostatin inhibitors eventually be used for?
Conditions involving progressive loss of skeletal muscle remain a major area of research.
Selective myostatin inhibition has reached advanced clinical research for neuromuscular disease.
Preserving muscle during ageing could eventually become another important application.
Combining weight loss medicines with muscle preserving therapies is now one of the most commercially significant areas of research.
Are myostatin inhibitors available in Australia?
Australians searching for myostatin inhibitors should distinguish between experimental pharmaceutical research and products marketed online using similar terminology.
Drugs such as trevogrumab and apitegromab are sophisticated monoclonal antibodies being developed through formal pharmaceutical research programs.
They should not be confused with supplements or unverified research products marketed as “myostatin blockers”.
The compounds discussed in this article are not being presented as established muscle building treatments for healthy Australians.
A product sold online using the name of a biological pathway does not mean it is equivalent to the drug used in a published study. Compound identity, manufacturing method, purity and biological activity all matter.
Animal research compared with human research
| Evidence | What researchers observed | What it tells us |
|---|---|---|
| Genetic myostatin deficiency | Very large increases in muscularity in several animal species | Strong evidence that myostatin is an important regulator of skeletal muscle |
| JA16 adult mouse study | Approximately 13% to 30% increases across individual skeletal muscles | Shows temporary pharmacological inhibition can affect adult muscle mass |
| 2025 obese mouse research | Lean mass preserved or increased while fat mass decreased | Suggests muscle and fat loss can potentially be influenced separately |
| 2025 primate research | Improved lean mass preservation during semaglutide induced weight loss | Supports the concept in an animal model closer to humans |
| COURAGE human trial | Trevogrumab prevented about half of semaglutide related lean mass loss | Evidence that direct myostatin inhibition can meaningfully affect human body composition |
So can you really build muscle without working out?
The animal evidence shows that myostatin inhibition can increase muscle without a resistance training program.
That part of the research is real.
What has not been demonstrated is a widely available and well studied medicine that allows healthy humans to safely gain enormous amounts of functional muscle while doing nothing.
Human evidence currently looks much more measured.
Researchers are demonstrating improved lean mass preservation and meaningful changes in body composition.
Whether newer and more selective myostatin inhibitors eventually produce larger muscle gains in humans remains one of the major unanswered questions in the field.
What happens next with myostatin inhibitors?
Researchers no longer need to prove that myostatin affects muscle mass.
The more important questions now relate to how the pathway can be used safely and effectively.
The first major use of myostatin inhibitors may not be extreme muscle growth. It may be helping people lose substantial amounts of body fat while keeping more of their existing muscle.
Frequently asked questions
What is a myostatin inhibitor?
A myostatin inhibitor is an experimental drug or therapy designed to reduce the activity of myostatin, a protein involved in limiting skeletal muscle growth.
Can blocking myostatin really build muscle?
Yes. Animal research has repeatedly shown increased skeletal muscle mass when myostatin signalling is reduced. An early adult mouse study reported increases of approximately 13% to 30% across individual skeletal muscles.
Can myostatin inhibitors build muscle without exercise?
Animal studies have demonstrated increases in muscle without a resistance training intervention. This does not mean exercise is unnecessary because training produces many additional adaptations beyond muscle size.
What myostatin inhibitor was used in the recent animal study?
The 2025 Nature Communications research used trevogrumab to block myostatin and garetosmab to block activin A. The drugs were studied alongside semaglutide in obese mice and cynomolgus monkeys.
What is trevogrumab?
Trevogrumab, previously known as REGN1033, is an investigational monoclonal antibody developed by Regeneron that binds to and inhibits myostatin.
What is apitegromab?
Apitegromab is a selective monoclonal antibody developed by Scholar Rock. It targets inactive precursor forms of myostatin before the protein becomes biologically active.
Are myostatin inhibitors steroids?
No. Myostatin inhibitors and anabolic steroids affect different biological pathways. Myostatin inhibitors reduce signalling that restricts muscle growth, while anabolic steroids primarily act through androgen receptors.
Are myostatin inhibitors peptides?
Not necessarily. Several of the most advanced myostatin inhibitors are monoclonal antibodies rather than conventional research peptides.
Are myostatin inhibitors available in Australia?
The pharmaceutical compounds discussed in this article remain experimental or specialist therapies rather than established muscle building medicines for healthy Australians. Products marketed online as myostatin blockers should not be assumed to be equivalent to pharmaceutical compounds used in published studies.
The bottom line
Myostatin is a genuine biological regulator of skeletal muscle growth.
Blocking the pathway has produced significant increases in muscle mass in animal studies.
One early experiment reported approximately 13% to 30% increases across individual muscles in adult mice after only two to four weeks of myostatin inhibition.
More recent research has shown that myostatin and activin A blockade can preserve or even increase lean mass during substantial weight loss in obese animals.
Human research is now showing meaningful effects as well.
Trevogrumab has demonstrated the ability to preserve a substantial proportion of the lean mass otherwise lost during semaglutide treatment.
However, the extreme muscle growth associated with genetic myostatin deficiency has not been reproduced as a safe and established treatment for healthy humans.
The pathway clearly works. The remaining challenge is determining how much it can safely change human muscle mass, strength and body composition over the long term.
Research sources
- Whittemore LA, Song K, Li X, et al. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochemical and Biophysical Research Communications. 2003. View study →
- Mastaitis JW, Gomez D, Raya JG, et al. GDF8 and activin A blockade protects against GLP-1 induced muscle loss while enhancing fat loss in obese male mice and non-human primates. Nature Communications. 2025. View study →
- Regeneron Pharmaceuticals. Phase 2 COURAGE trial results investigating trevogrumab alongside semaglutide. View results →
- ClinicalTrials.gov. COURAGE study of trevogrumab and garetosmab alongside semaglutide. NCT06299098. View trial →
- Scholar Rock. Apitegromab and selective myostatin inhibition research. View research →